Punchalee Kaenmuang👩🏻⚕️ Pulmonologist 📍Prince of Songkla University 📚
Thailand
Joined March 2018
- Tweets831
- Following675
- Followers195
- Likes933
Pinned Tweet
Thrilled to share our work “Peripheral white cell counts and #mortality across different ILD” at the #ERSCongress2024.
Our study includes data from 1,186 patients with fibrotic ILD from @RBandH.
Thanks for all support!
And many thanks @ActionPFcharity for the conference award
Back in Thailand after ERS Congress 2026. Highlights: abstract reviewer, chairing 2 poster sessions, clinical research discussions (TRANSLATE-ILA & EXPLAIN-IT), reconnecting with colleagues, and joining the ERS Guidelines Methodology Network. Grateful & inspired. #ERSCongress2026
PunchaleeK retweeted
Clinical features that associate with mucus plug-high phenotypes of asthma and COPD DOI: 10.1183/13993003.02358-2025 @ERSpublications
PunchaleeK retweeted
#Clinical # of #difficult-to-treat and #mild #asthma defined by #cluster #analysis. Open Access. interasma.org/2026/06/04/cli…
PunchaleeK retweeted
#Depemokimab reduces #asthma #exacerbations similarly to other #biologics: systematic trial review and indirect treatment comparison. Open Access. interasma.org/2026/05/31/dep…
PunchaleeK retweeted
Impact of #Biologics Administered for Severe #Asthma on #T2-#comorbidities: A Narrative Review Open Access. interasma.org/2026/05/25/imp…
PunchaleeK retweeted
Association of bronchoalveolar lavage cellular analysis and radiological findings in fibrotic interstitial lung diseases. bit.ly/3Pr92c9
#BMJ_ORR #RespiratoryResearch #OpenAccess #Pulmonology #MedicalResearch
PunchaleeK retweeted
Some caution is necessary…
If we have symptoms there os already a disease !
#COPD
[ @suryapbhatt ]
#ATS2026
PunchaleeK retweeted
Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: a multicenter, randomized, double-blind, phase 3A clinical trial (NIMBLE)
🎙️Part of today’s JAMA/NEJM/AJRCCM Pulmonary Session #ATS2026
doi.org/10.1093/ajrccm/aamag…
@atscommunity
PunchaleeK retweeted
Presented today at #ATS2026 ⤵️
Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebocontrolled, phase 2b and 3 trials
spkl.io/6018AC97w @atscommunity
ALT Figure: Primary endpoint in ALIENTO and ARNASA. Adjusted annualised rate of moderate or severe COPD exacerbations. COPD=chronic obstructive pulmonary disease. mITT=modified intention-to-treat. RR=rate ratio. Copyright: 2026 Elsevier Ltd. All rights reserved.
PunchaleeK retweeted
BSR vs ACR vs EULAR Monitoring Guidelines for SARD-ILD
#Rheumatology #MedTwitter
PunchaleeK retweeted
Blood eosinophil count is a key biomarker for guiding corticosteroids and biologic therapies in eosinophilic COPD and asthma, enabling precision treatment that targets those most likely to benefit while reducing unnecessary exposure and adverse effects bit.ly/3NyuFpI
PunchaleeK retweeted
A CHEST Review aims to provide an overview of the literature for subclinical rheumatoid arthritis-associated interstitial lung disease (RA-ILD).
Read more in the April issue of the journal CHEST®: hubs.ly/Q047lj2N0
#MedEd #JournalCHEST #LungDisease
PunchaleeK retweeted
ERJ Open Research: In addition to exacerbation history, numerous factors are known to increase the risk of COPD exacerbations. This prospective study has shown that these predictors differ between mild, moderate and severe/very severe airflow limitation. bit.ly/45og5HC
It is my honour to have given a talk on post-tuberculosis bronchiectasis at the 10th Asia Pacific Region Conference of the International Union Against Tuberculosis and Lung Disease (#APRC 2026), held this year in Thailand.
#Tuberculosis #bronchiectasis #fibrosis
PunchaleeK retweeted
One of the most important metric for deciding to start a patient on a new treatment is NNT (number-needed-to-treat). Here, Mohsen and I discuss NNT in the context of #dupilumab for #COPD. You will find out the difference btn event vs person-based NNT.
bit.ly/3UGhumT
